ClinicalTrials.gov
public full text
Public Domain
Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Screening of New Markers of Gut Microbiota in Stroke and Depression: a Cross-sectional Study#830923
- Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach#841110
- Encapsulated faecal microbiota transfer to target immune activation in patients with cirrhosis and ascites (TransImmune): protocol for a randomised, double-blind, Phase IIa, placebo-controlled trial / Karsten Große, Frederic Haedge, Carmen Fera, Jana Hecker, Jan Wienstroer, Anastasia Tsakmaklis, Andreas Fichtner, Nicole S. Treichel, Thomas Clavel, Theresa Wirtz, Oliver Pabst, Rainer Schuckelt, Maria JGT Vehreschild, Tony Bruns#629000
- Epigenetic Effect Modifications With Ozone Exposure on Healthy Volunteers#812758
- From Nature to Bedside- Algae Based Bio Compound for Prevention and Treatment of Inflammation, Pain and IBD#1007621
Record · ID 444894
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive